Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kura Oncology (KURA) Leases (2022 - 2026)

Kura Oncology has reported Leases over the past 5 years, most recently at $7.2 million for Q1 2026.

  • Quarterly Leases fell 11.95% to $7.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Mar 2026, down 11.95% year-over-year, with the annual reading at $7.3 million for FY2025, 25.83% up from the prior year.
  • Leases was $7.2 million for Q1 2026 at Kura Oncology, down from $7.3 million in the prior quarter.
  • Over five years, Leases peaked at $8.1 million in Q1 2025 and troughed at $2.9 million in Q2 2023.
  • The 5-year median for Leases is $6.8 million (2023), against an average of $6.2 million.
  • The largest YoY upside for Leases was 118.21% in 2024 against a maximum downside of 17.02% in 2024.
  • A 5-year view of Leases shows it stood at $3.8 million in 2022, then surged by 82.01% to $7.0 million in 2023, then fell by 17.02% to $5.8 million in 2024, then grew by 25.83% to $7.3 million in 2025, then fell by 1.86% to $7.2 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Leases are $7.2 million (Q1 2026), $7.3 million (Q4 2025), and $7.5 million (Q3 2025).